Xenon Pharmaceuticals (XENE) Aktienübersicht
Xenon Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen mit Schwerpunkt auf den Neurowissenschaften, das sich mit der Entdeckung, Entwicklung und Bereitstellung von Therapeutika zur Behandlung von Patienten mit neurologischen und psychiatrischen Störungen befasst. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
XENE Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Xenon Pharmaceuticals Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$59.73 |
| 52-Wochen-Hoch | US$72.66 |
| 52-Wochen-Tief | US$35.60 |
| Beta | 0.63 |
| 1 Monat Veränderung | -10.50% |
| 3 Monate Veränderung | 10.26% |
| 1 Jahr Veränderung | 56.44% |
| 3 Jahre Veränderung | 55.95% |
| 5 Jahre Veränderung | 251.35% |
| Veränderung seit IPO | 468.86% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Aug 11
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity
Summary Xenon Pharmaceuticals (XENE) is upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results for azetukalner in focal onset seizures [FOS]. Company plans NDA filing for azetukalner in FOS in Q3 2026, with X-TOLE3 supporting potential ex-US expansion. Major depressive disorder [MDD] is a key pipeline focus, with phase 3 X-NOVA2 topline data expected in 1H 2027. Robust $1.2B cash position funds operations into 2029, supporting multiple late-stage programs and pipeline expansion. Read the full article on Seeking Alpha
Narrative-Update • Aug 09
XENE: Upcoming NDA Filing And Kv7 Data Readouts Will Shape Risk Balance
Analysts lifted their fair value estimate for Xenon Pharmaceuticals to $69 from $63, citing updated models that reflect recent Street research and revised long term assumptions on revenue potential, margins, and future P/E expectations. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights both interest in the epilepsy opportunity and a set of clear caution flags that investors should factor into expectations for execution and valuation risk.
Narrative-Update • Jul 10
XENE: Epilepsy Trial Progress Will Define Edge Versus Slower Kv7 Rival
Analysts have lifted their fair value estimate for Xenon Pharmaceuticals from about $55.40 to about $80.56, reflecting updated models that incorporate revised assumptions for long term revenue potential, profit margins, and future P/E multiples in light of recent Street research and competitive positioning versus Biohaven. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights a mix of optimism on the epilepsy opportunity and caution around execution and competitive risk, particularly in comparison with Biohaven.Narrative-Update • Jun 26
XENE: Phase 3 Success And Mixed Street Views Will Shape Next Chapter
The updated analyst price target for Xenon Pharmaceuticals has moved from $58.58 to $63.00, as analysts factor in refreshed models and recent Street research that includes higher targets from firms such as JPMorgan and Wells Fargo, alongside a modest trim from Needham. Analyst Commentary Recent Street research on Xenon Pharmaceuticals shows a mixed tone, with some large firms, including JPMorgan, lifting price targets while other bearish analysts trim expectations.Recent updates
Seeking Alpha • Aug 11
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity
Summary Xenon Pharmaceuticals (XENE) is upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results for azetukalner in focal onset seizures [FOS]. Company plans NDA filing for azetukalner in FOS in Q3 2026, with X-TOLE3 supporting potential ex-US expansion. Major depressive disorder [MDD] is a key pipeline focus, with phase 3 X-NOVA2 topline data expected in 1H 2027. Robust $1.2B cash position funds operations into 2029, supporting multiple late-stage programs and pipeline expansion. Read the full article on Seeking AlphaNarrative-Update • Aug 09
XENE: Upcoming NDA Filing And Kv7 Data Readouts Will Shape Risk Balance
Analysts lifted their fair value estimate for Xenon Pharmaceuticals to $69 from $63, citing updated models that reflect recent Street research and revised long term assumptions on revenue potential, margins, and future P/E expectations. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights both interest in the epilepsy opportunity and a set of clear caution flags that investors should factor into expectations for execution and valuation risk.Narrative-Update • Jul 10
XENE: Epilepsy Trial Progress Will Define Edge Versus Slower Kv7 Rival
Analysts have lifted their fair value estimate for Xenon Pharmaceuticals from about $55.40 to about $80.56, reflecting updated models that incorporate revised assumptions for long term revenue potential, profit margins, and future P/E multiples in light of recent Street research and competitive positioning versus Biohaven. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights a mix of optimism on the epilepsy opportunity and caution around execution and competitive risk, particularly in comparison with Biohaven.Narrative-Update • Jun 26
XENE: Phase 3 Success And Mixed Street Views Will Shape Next Chapter
The updated analyst price target for Xenon Pharmaceuticals has moved from $58.58 to $63.00, as analysts factor in refreshed models and recent Street research that includes higher targets from firms such as JPMorgan and Wells Fargo, alongside a modest trim from Needham. Analyst Commentary Recent Street research on Xenon Pharmaceuticals shows a mixed tone, with some large firms, including JPMorgan, lifting price targets while other bearish analysts trim expectations.Neues Narrative • Mar 27
Epilepsy And Depression Pipeline Will Define Fair Long Term Outlook
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel based therapies for epilepsy, depression, bipolar disorder and pain. What are the underlying business or industry changes driving this perspective?
Neues Narrative • Mar 09
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel targeted medicines for epilepsy, neuropsychiatric conditions and pain. What are the underlying business or industry changes driving this perspective?Analyseartikel • Oct 01
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Apr 18
Xenon- A Later Stage Story
Summary Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming phase III data expected by end of 2025. Azetukalner's unique Kv7 potassium channel mechanism and rapid onset of action could address unmet needs in treatment-resistant epilepsy and potentially depression. Financially stable, Xenon is well-funded into 2027, with potential $1Bn market opportunity if azetukalner succeeds in focal onset seizures and expands into other indications. Despite broader biotech market challenges, Xenon's strong efficacy and safety data position it well, with significant interest from major pharma in neurology and neuropsychiatry. Read the full article on Seeking AlphaSeeking Alpha • Jan 16
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Summary Xenon Pharmaceuticals' Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should last into 2027 or more. So, I think it should have enough resources to take its late-stage pipeline to approval. Epilepsy and MDD have an attractive TAM of several billions of dollars in the US and abroad. XENE could tap into these niche markets over time. I also believe its late-stage IP is diversified with ion channel modulators for pain and other neurological conditions. So it’s not overly exposed to Azetukalner. I concede that XENE has a premium valuation, but I think 2025 will provide significant clinical data that could justify a “Buy” rating at these levels. Read the full article on Seeking AlphaSeeking Alpha • Aug 09
Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Summary Xenon Pharmaceuticals is a Canadian biopharma company targeting neurological diseases with a focus on ion channel-blocking technology. The clinical stage asset, azetukalner, is in late stage development for epilepsy and Major Depressive Disorder, showing promising results in reducing seizure frequency. Despite a history of failures and low trading volume, Xenon has a strong cash position and upcoming catalysts in phase 3 trials for their lead asset. Read the full article on Seeking AlphaSeeking Alpha • Feb 08
Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Summary Today, we focused on Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics for neurological disorders. The company has experienced "setbacks" in recent trials, but its primary drug candidate, XEN1101, shows significant potential for treating epilepsy. Xenon has initiated Phase 3 clinical trials for XEN1101 and has received myriad positive ratings from analysts, but the stock may be vulnerable to profit-taking. An analysis around Xenon Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Oct 19
Xenon started at outperform at Raymond James on experimental epilepsy drug
Raymond James has initiated Xenon Pharmaceuticals (NASDAQ:XENE) with an outperform rating citing the blockbuster potential of XEN1101, currently in phase 2 for epilepsy. The firm has a $52 price target (~46% upside based on Tuesday's close). Analyst Danielle Brill is confident that XEN1101 will be successful given its strong phase 2 results. She predicted a greater than $1B peak sales opportunity. Xenon (XENE) plans to initiate two identical phase 3 clinical trials. She noted that the the candidate, which is also under development for major depressive disorder, could further benefit from proof-of-concept data in that indication expected in 2023. Brill added that the company's pipeline also presents growth opportunities with XEN496 in KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE), and NBI-921352 for SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). XEN1101 is also under investigation for primary generic clonic tonic seizures (PGTCS). In August, BofA started Xenon (XENE) with a buy rating also citing the blockbuster potential of XEN1101 for epilepsy.Seeking Alpha • Sep 06
Putting Xenon Pharmaceuticals Back In The Spotlight
Summary Today, we are revisiting Xenon Pharmaceuticals for the first time in 2022. The company is well-funded and advancing several compounds in its pipeline, one of which might have blockbuster potential. An investment analysis follows in the paragraphs below. "Potential has a shelf life." - Margaret Atwood We last looked in on Xenon Pharmaceuticals (XENE) nearly nine months ago. In the summary of that article, the conclusion was that the company had some promising attributes and was worthy of a small 'watch item' via covered call positions. That turned out to be a profitable trade. Time for another potential round trip? We update the investment thesis on Xenon below. Seeking Alpha Company Overview: Xenon Pharmaceuticals is a clinical-stage biotech company focused on developing therapeutics to treat patients with neurological disorders. The company is based just outside of Vancouver, Canada. The stock trades just under $40.00 a share and sports an approximate market cap just north of $2.4 billion. August Company Presentation The company has several compounds in development as can be seen by the pipeline chart above. August Company Presentation The most important asset in development is a candidate called for the moment XEN1011. This is a next generation Kv7 potassium channel opener with potential applications in treating the focal onset seizures which occurs in epileptics as well as other potential neurological disorders. August Company Presentation A Phase 2b trial produced encouraging results in the fourth quarter of last year. The company then disclosed new, compelling efficacy data from that study 'X-TOLE' in June of this year. A Phase 2 study 'X-TOLE2' should initiate by the end of this year, followed shortly by a Phase 3 trial X-TOLE3. If successful, the company plans to submit a market application around this compound to treat epilepsy. August Company Presentation The compound is also in development for other neurological disorders. The company currently has a Phase 2 'X-NOVA' study underway examining XEN1101 in major depressive disorder or MDD. This trial in parallel with an investigator-led Phase 2 MDD study led by Xenon's collaborators at Mount Sinai. Topline results should be out in 2023. August Company Presentation XEN1101 is also now targeting primary generalized tonic clonic seizures or PGTCS. Management plans to initiate a Phase 3 clinical trial, called X-ACKT, to support potential regulatory submissions in PGTCS. This study should kick soon after initiation of the X-TOLE2 trial. August Company Presentation Another compound 'XEN496' is being developed to treat rare KCNQ2-DEE pediatric epilepsy. A Phase 3 study called EPIK, is ongoing to evaluate the efficacy, safety, and tolerability of XEN496 administered as adjunctive treatment in approximately 40 pediatric patients aged one month to less than six years with KCNQ2-DEE. This trial should complete sometime in 2023. August Company Presentation Finally the company has licensed a selective Nav1.6 sodium channel inhibitor 'XEN901', now known as NBI-921352, to Neurocrine Biosciences (NBIX). That compound is in Phase 2 development for a couple of indications. As the result of this licensing agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties on any eventual commercialization. Analyst Commentary & Balance Sheet: Since second quarter results were posted on August 9th, five analyst firms including Needham and Wedbush have reissued Buy ratings on XENE. Price targets proffered ranged from $46 to $52 a share. On August 29th, Bank of America initiated the shares as a new Buy with a $45 a share price target. Here is the commentary from the bank's analyst at the time of that call.Seeking Alpha • Aug 29
Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Bank of America launched its coverage on clinical-stage biotech Xenon Pharmaceuticals Inc. (NASDAQ:XENE) with a Buy rating on Monday, arguing that the company’s mid-stage epilepsy candidate XEN1101 is poised to become a blockbuster drug. XEN1101 belongs to a class of drugs known as Kv7 potassium channel openers, and the drug is expected to undergo its Phase 3 program in H2 2022, XENE said this month. The analysts led by Jason M. Gerberry point to the blockbuster potential of XEN1101 ahead of important catalysts for its safety data, second confirmatory, and label expansion studies. The ease of use, novel mechanism of action, and strong efficacy differentiate XEN1101 from other anti-seizure medications, the team with a $48 per share target on XENE argued. Wall Street stands firmly behind the prospects of Xenon (XENE) with eleven Buy ratings and no Hold or Sell ratings.Seeking Alpha • Dec 13
Sizing Up Xenon Pharmaceuticals
Today, we look at Xenon Pharmaceuticals, a clinical-stage biotech concern with several products advancing in its pipeline. The stock recently has surged on top of positive mid-stage trial results. The shares have also seen some insider buying lately as well. A full investment analysis follows in the paragraphs below.Aktionärsrenditen
| XENE | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -7.0% | 6.2% | -0.8% |
| 1Y | 56.4% | 46.3% | 20.5% |
Rendite im Vergleich zur Industrie: XENE übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 46.3 erzielte.
Rendite vs. Markt: XENE übertraf den Markt US, der im vergangenen Jahr eine Rendite von 20.5 erzielte.
Preisvolatilität
| XENE volatility | |
|---|---|
| XENE Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: XENE hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: XENEDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | 364 | Ian Mortimer | www.xenon-pharma.com |
Xenon Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen mit Schwerpunkt auf den Neurowissenschaften, das sich mit der Entdeckung, Entwicklung und Bereitstellung von Therapeutika zur Behandlung von Patienten mit neurologischen und psychiatrischen Störungen befasst. Zu den Produktkandidaten des Unternehmens gehört Azetukalner, ein neuartiger, potenter Kv7-Kaliumkanalöffner, der sich in der klinischen Phase 3 zur Behandlung von Epilepsie, einschließlich fokal einsetzender Anfälle und primär generalisierter tonisch-klonischer Anfälle, sowie von neuropsychiatrischen Störungen wie Major Depression und bipolarer Depression befindet. Darüber hinaus gehören zu den Phase-1-Produkten des Unternehmens XEN1701, das auf den Natriumkanal abzielt, und XEN1120, das auf den Kaliumkanal Kv7 abzielt, für die Behandlung von Schmerzen.
Xenon Pharmaceuticals Inc.'s Grundlagenzusammenfassung
| XENE grundlegende Statistiken | |
|---|---|
| Marktanteil | US$6.04b |
| Gewinn(TTM) | -US$409.19m |
| Umsatz(TTM) | n/a |
0.0x
Kurs-Umsatz-Verhältnis-14.1x
Kurs-Gewinn-Verhältnis Ist XENE zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| XENE Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$0 |
| Kosten der Einnahmen | US$352.49m |
| Bruttogewinn | -US$352.48m |
| Sonstige Ausgaben | US$56.71m |
| Gewinn | -US$409.19m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -4.23 |
| Bruttomarge | 0.00% |
| Nettogewinnspanne | 0.00% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich XENE auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/20 01:12 |
| Aktienkurs zum Tagesende | 2026/08/20 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Xenon Pharmaceuticals Inc. wird von 25 Analysten beobachtet. 17 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| John Newman | Canaccord Genuity |